Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Jakafi (ruxolitinib) Indication(s): Intermediate or highrisk myelofibrosis, polycythemia vera (after hydroxyurea failure), acute graftversushost disease (GVHD) and chronic GVHD in adults (and pediatric patients 12 years and older) Manufacturer(s): Incyte (in the US)/Novartis 2024 Sales: $4.73 billion Why it sold so well: Jakafi generated approximately $2.8 billion in sales in 2024, marking a solid 8% YoY increase
Consult your health care practitioner if you are nursing/lactating, taking medications or have a medical condition, before taking this or any other product
Detailed cycling strategies for various peptides are covered in the cycle planning guide , and the question of cycling different peptides is addressed with specific protocol examples
Notably, we detected a marked reduction in NRF2 expression in the lesioned skin of both clinical biopsy samples and the IMQ-induced psoriatic mouse model
US$ 26.72
US$ 22.97
US$ 26.96
US$ 20.55
US$ 28.33
US$ 21.50
